Aimovig (erenumab-aooe subcutaneous injection – Amgen) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has ≥ 4 migraine headache days per month (prior to initiating a migraine-preventive medication)
• If patient is currently taking Aimovig, the patient has had a significant clinical benefit from the medication, as determined by the prescriber

Reauthorization criteria

• Patient continues to derive significant clinical benefit from Aimovig as determined by the prescriber

Approval duration

1 year